A pivotal phase 3 study of cabozantinib to treat patients with advanced differentiated thyroid carcinoma (DTC).
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Registrational; Therapeutic Use
- Sponsors Exelixis
- 27 Feb 2018 New trial record
- 26 Feb 2018 Accoding to a Exelixis media release, company plans to initiate the trial later in 2018.